Quanterix Partners with Tempus AI to Launch Alzheimer's Blood Test
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 4 days ago
0mins
Should l Buy QTRX?
Lucent Diagnostics, a brand of Quanterix Corporation (QTRX), announced a collaboration with Tempus AI (TEM) to broaden access to a novel blood-based biomarker panel designed to improve detection accuracy for Alzheimer's disease. Through the agreement, Tempus AI will build a Tempus Next care gap program for Alzheimer's disease blood-based biomarker testing, with the LucentAD Complete multi-biomarker blood test becoming available for neurologists to order on the Tempus clinical ordering platform. "This collaboration represents an important step toward ensuring blood-based Alzheimer's biomarker testing becomes part of routine clinical practice - without placing additional burden on providers," said Everett Cunningham, CEO of Quanterix. "By working with Tempus to integrate LucentAD Complete into the clinical ordering workflow, we are helping reduce barriers to access and equipping neurologists with a more seamless, non-invasive approach to identifying amyloid-positive patients who may benefit from approved therapies. As we look to advance precision health through high-sensitivity biomarker innovation, collaborations that streamline the diagnostic journey are essential to support earlier, more confident clinical decisions."
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy QTRX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on QTRX
Wall Street analysts forecast QTRX stock price to rise
2 Analyst Rating
0 Buy
2 Hold
0 Sell
Hold
Current: 2.750
Low
7.00
Averages
7.50
High
8.00
Current: 2.750
Low
7.00
Averages
7.50
High
8.00
About QTRX
Quanterix Corporation is a life sciences company. The Company is focused on ultra-sensitive biomarker detection, enabling breakthroughs in disease research, diagnostics, and drug development proprietary digital Simoa detection technology enables customers to reliably detect protein biomarkers at ultra-low concentrations in blood, serum and other fluids that, in many cases, are undetectable using conventional, analog immunoassay technologies. Its Simoa bead-based digital immunoassays utilize the basic principles of conventional bead-based sandwich ELISA. The HD-X is the Company's flagship instrument that empowers biomarker research and accelerates drug development. Its SR-X instrument is a compact benchtop instrument with a lower price point, more flexible assay preparation, and a wider range of applications. The Company's Spatial Biology solutions measure protein expression and cellular phenotypes within intact tissue while preserving spatial context and tissue architecture.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Quanterix Q1 2026 Earnings Call Insights
- Market Leadership: Quanterix maintains its market leadership in early disease biomarker detection with over 2,300 installed instruments and approximately $100 million in cash with no debt, indicating a clear path towards profitability in its research tools business.
- Revenue Performance: In Q1 2026, Quanterix reported revenue of $36.4 million, reflecting challenges in market conditions, although consumable revenues performed as planned while instrumentation revenue was slightly softer than expected, highlighting demand pressures.
- Strategic Investments: The company is increasing investments in its Alzheimer's diagnostics business, including hiring a new diagnostics leader and upgrading the Simoa HD-X platform, with plans to file for IVD status with the FDA in 2027 to support future market needs.
- Commercial Partnerships: Quanterix announced an important partnership with Tempus AI to integrate LucentAD Complete into electronic health record systems at select locations, utilizing a proprietary algorithm to flag patients meeting clinical criteria, aiming to enhance market penetration.
See More
Quanterix Q1 Earnings Beat Expectations Despite Revenue Miss
- Earnings Beat: Quanterix reported a Q1 GAAP EPS of -$0.37, beating expectations by $0.14, indicating improvements in cost management despite still posting a negative profit.
- Revenue Miss: The company achieved a revenue of $36.42M, reflecting a 20.2% year-over-year growth, yet it fell short of expectations by $0.42M, suggesting weak market demand that could undermine investor confidence moving forward.
- Future Revenue Target: Quanterix aims for a revenue target of $169M to $174M by 2026, focusing on diagnostics and cost synergies, which indicates a clear strategic direction aimed at enhancing long-term growth potential.
- Stock Reaction: Following the earnings report, Quanterix shares fell 2% in after-hours trading, reflecting market caution regarding the results and potentially impacting short-term investor sentiment and market performance.
See More
Quanterix to Host Q1 2026 Financial Results Conference Call on May 6, 2026
- Conference Call Announcement: Quanterix Corporation announced it will host a conference call on May 6, 2026, at 4:30 PM ET to discuss its Q1 2026 financial results, with the press release expected to enhance investor understanding of the company's performance after market close.
- Dial-In Information: The dial-in numbers for the conference are Toll-Free (800) 715-9871 or (646) 307-1963 for the USA and Canada, with conference ID 8523507, ensuring easy access for investors to participate and receive the latest updates.
- Live Webcast and Replay: Investors can listen to the live webcast from the Investors section of the Quanterix website, with an archived replay available for one year post-event, further enhancing information transparency and investor engagement.
- Technological Leadership: Quanterix is a global leader in ultra-sensitive biomarker detection, with its proprietary Simoa® technology enabling researchers to detect and quantify biomarkers at concentrations far below traditional limits, advancing precision medicine from discovery to diagnostics.
See More
AidaBREAST™ First to Predict Recurrence Risk in Early-Stage Breast Cancer
- Innovative Diagnostic Tool: AidaBREAST™ is the first multi-omic assay capable of predicting both locoregional recurrence risk and radiation therapy benefit for early-stage invasive breast cancer patients, marking a significant milestone in the clinical translation of spatial proteomics.
- Clinical Validation Data: The assay was validated in a cohort of 922 hormone receptor-positive, HER2-negative breast cancer patients across four academic and clinical centers in the U.S. and Sweden, with a median follow-up of approximately 10 years, demonstrating its effectiveness in predicting 10-year locoregional recurrence risk and radiation therapy benefit.
- Technological Advantage: AidaBREAST leverages the PhenoImager HT platform and Opal chemistry, integrating targeted next-generation RNA sequencing for a comprehensive assessment of tumor biology, enabling physicians to make more personalized treatment decisions.
- Industry Impact: The collaboration between PreludeDx and Quanterix showcases the potential of spatial proteomics in clinical oncology, with the launch of AidaBREAST poised to advance personalized medicine and assist patients and physicians in making more informed treatment choices.
See More
Quanterix Unveils Content Innovation Engine to Advance Cancer Biology Research
- Content Innovation Engine Launch: Quanterix announced the debut of its Content Innovation Engine at the 2026 AACR Annual Meeting, integrating Akoya's spatial biology platform with Quanterix's ultra-sensitive immunoassay technology to systematically unlock cancer biology and accelerate clinical applications.
- Edison Award Nomination: The PhenoCode™ Discovery IO60 panel has been named a finalist for the Edison Awards, showcasing its deep coverage in immunotherapy biology, particularly in key therapeutic markers such as PD-1/PD-L1 and CTLA-4.
- New Product Introduction: Quanterix will introduce the PhenoCode Molecular Barcoding Kit at AACR, enabling researchers to barcode virtually any antibody with exceptional reliability and yield, with early access expected to begin in May 2026.
- ADC Lung Cancer Panels: Quanterix will present two new ADC lung cancer panels at AACR, building on the success of its ADC breast cancer panel, now available as a fully managed service, further advancing cancer research efforts.
See More
Quanterix (QTRX) Q4 2025 Earnings Call Transcript
See More
Quanterix Q1 2026 Earnings Call Insights
- Market Leadership: Quanterix maintains its market leadership in early disease biomarker detection with over 2,300 installed instruments and approximately $100 million in cash with no debt, indicating a clear path towards profitability in its research tools business.
- Revenue Performance: In Q1 2026, Quanterix reported revenue of $36.4 million, reflecting challenges in market conditions, although consumable revenues performed as planned while instrumentation revenue was slightly softer than expected, highlighting demand pressures.
- Strategic Investments: The company is increasing investments in its Alzheimer's diagnostics business, including hiring a new diagnostics leader and upgrading the Simoa HD-X platform, with plans to file for IVD status with the FDA in 2027 to support future market needs.
- Commercial Partnerships: Quanterix announced an important partnership with Tempus AI to integrate LucentAD Complete into electronic health record systems at select locations, utilizing a proprietary algorithm to flag patients meeting clinical criteria, aiming to enhance market penetration.
See More
Quanterix Q1 Earnings Beat Expectations Despite Revenue Miss
- Earnings Beat: Quanterix reported a Q1 GAAP EPS of -$0.37, beating expectations by $0.14, indicating improvements in cost management despite still posting a negative profit.
- Revenue Miss: The company achieved a revenue of $36.42M, reflecting a 20.2% year-over-year growth, yet it fell short of expectations by $0.42M, suggesting weak market demand that could undermine investor confidence moving forward.
- Future Revenue Target: Quanterix aims for a revenue target of $169M to $174M by 2026, focusing on diagnostics and cost synergies, which indicates a clear strategic direction aimed at enhancing long-term growth potential.
- Stock Reaction: Following the earnings report, Quanterix shares fell 2% in after-hours trading, reflecting market caution regarding the results and potentially impacting short-term investor sentiment and market performance.
See More
Quanterix to Host Q1 2026 Financial Results Conference Call on May 6, 2026
- Conference Call Announcement: Quanterix Corporation announced it will host a conference call on May 6, 2026, at 4:30 PM ET to discuss its Q1 2026 financial results, with the press release expected to enhance investor understanding of the company's performance after market close.
- Dial-In Information: The dial-in numbers for the conference are Toll-Free (800) 715-9871 or (646) 307-1963 for the USA and Canada, with conference ID 8523507, ensuring easy access for investors to participate and receive the latest updates.
- Live Webcast and Replay: Investors can listen to the live webcast from the Investors section of the Quanterix website, with an archived replay available for one year post-event, further enhancing information transparency and investor engagement.
- Technological Leadership: Quanterix is a global leader in ultra-sensitive biomarker detection, with its proprietary Simoa® technology enabling researchers to detect and quantify biomarkers at concentrations far below traditional limits, advancing precision medicine from discovery to diagnostics.
See More
AidaBREAST™ First to Predict Recurrence Risk in Early-Stage Breast Cancer
- Innovative Diagnostic Tool: AidaBREAST™ is the first multi-omic assay capable of predicting both locoregional recurrence risk and radiation therapy benefit for early-stage invasive breast cancer patients, marking a significant milestone in the clinical translation of spatial proteomics.
- Clinical Validation Data: The assay was validated in a cohort of 922 hormone receptor-positive, HER2-negative breast cancer patients across four academic and clinical centers in the U.S. and Sweden, with a median follow-up of approximately 10 years, demonstrating its effectiveness in predicting 10-year locoregional recurrence risk and radiation therapy benefit.
- Technological Advantage: AidaBREAST leverages the PhenoImager HT platform and Opal chemistry, integrating targeted next-generation RNA sequencing for a comprehensive assessment of tumor biology, enabling physicians to make more personalized treatment decisions.
- Industry Impact: The collaboration between PreludeDx and Quanterix showcases the potential of spatial proteomics in clinical oncology, with the launch of AidaBREAST poised to advance personalized medicine and assist patients and physicians in making more informed treatment choices.
See More
Quanterix Unveils Content Innovation Engine to Advance Cancer Biology Research
- Content Innovation Engine Launch: Quanterix announced the debut of its Content Innovation Engine at the 2026 AACR Annual Meeting, integrating Akoya's spatial biology platform with Quanterix's ultra-sensitive immunoassay technology to systematically unlock cancer biology and accelerate clinical applications.
- Edison Award Nomination: The PhenoCode™ Discovery IO60 panel has been named a finalist for the Edison Awards, showcasing its deep coverage in immunotherapy biology, particularly in key therapeutic markers such as PD-1/PD-L1 and CTLA-4.
- New Product Introduction: Quanterix will introduce the PhenoCode Molecular Barcoding Kit at AACR, enabling researchers to barcode virtually any antibody with exceptional reliability and yield, with early access expected to begin in May 2026.
- ADC Lung Cancer Panels: Quanterix will present two new ADC lung cancer panels at AACR, building on the success of its ADC breast cancer panel, now available as a fully managed service, further advancing cancer research efforts.
See More
Quanterix (QTRX) Q4 2025 Earnings Call Transcript
See More
